Surgical management of female breast cancer patients after neo-adjuvant chemotherapy for infiltrating duct carcinoma | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2023, Issue 1, January 2023 | ||||
| DOI: 10.58675/2682-339X.1812 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Saif El-Din Mahmoud El-Soudani; Mohamed Abdel Fattah Imam; Osama El-Said Abdallah Mohammed | ||||
| Department of General Surgery, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt. | ||||
| Abstract | ||||
| Background; Neoadjuvant chemotherapy (NAC) is defined as standard of care for management of advanced breast cancer & is being used for females with earlier stage disease, however this therapy has been confined for those with inoperable breast cancer, Aim and objectives; to assess surgical management of woman breast cancer studied cases after neoadjuvant chemotherapy for infiltrating ductal carcinoma, Subjects & techniques; This research will be carried on 60 female studied cases ranging from 20-60 years old, who will be recruited from the surgical oncology department in AL-Hussein and Sayed Galal hospitals and Damanhour Oncology Center, Al-Azhar university hospitals and all patients have invasive ductal carcinoma of breast, Result; Patients showed remarkable respond to NAC by clinical examination and ultrasonographic investigation in 80% of patients become T2 instead of T3 before NAC. As regards to axillary response to NAC; 5667% of patients become N0, Conclusion; advanced breast cancer represented majority of breast cancer studied cases, who were mostly middle-aged women. Even though complete clinical response was less in research, neoadjuvant chemotherapy was useful in down staging tumour in majority of cases. If chemotherapy is regarded prior to mastectomy, rate of margin positivity in mastectomy specimens can be decreased. Knowing your receptor status can help you predict how you will respond to chemotherapy. | ||||
|
Statistics Article View: 11 |
||||
